LNC (Beijing) Biotechnology

LNC (Beijing) Biotechnology is a specialized biotechnology company focused on the development of live biotherapeutic products (LBPs) derived from the human gut microbiome. The company primarily targets metabolic and cardiometabolic diseases, including obesity and type 2 diabetes, by leveraging specific bacterial strains such as Christensenella. As a key player in the Chinese microbiome sector, LNC (Beijing) Biotechnology works on translating microbiome research into clinical applications through proprietary screening and manufacturing processes. The company's efforts are centered on establishing a robust pipeline of microbial-based therapies that modulate host metabolism to treat chronic conditions.